NCT03513211View on ClinicalTrials.gov

Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 23, 2018

Primary Completion Date

August 30, 2023

Study Completion Date

October 30, 2023

Conditions
Prostate Cancer
Interventions
DRUG

SUBA-itraconazole

150mg PO BD

DRUG

Hydroxychloroquine

Escalating doses in Rolling 6 Phase I

Trial Locations (1)

2010

St Vincent's Hospital, Darlinghurst

All Listed Sponsors
lead

St Vincent's Hospital, Sydney

OTHER

NCT03513211 - Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter